Carmen Calfa

740 total citations
40 papers, 406 citations indexed

About

Carmen Calfa is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Carmen Calfa has authored 40 papers receiving a total of 406 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 9 papers in Molecular Biology. Recurrent topics in Carmen Calfa's work include Advanced Breast Cancer Therapies (12 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Carmen Calfa is often cited by papers focused on Advanced Breast Cancer Therapies (12 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Carmen Calfa collaborates with scholars based in United States, India and Italy. Carmen Calfa's co-authors include Richard L. Schilsky, Elizabeth Garrett‐Mayer, Susan Halabi, Timothy Lewis Cannon, Pam K. Mangat, Eugene R. Ahn, Andrew L. Rygiel, Pamela Crilley, Kaitlyn R. Antonelli and Suanna S. Bruinooge and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Carmen Calfa

35 papers receiving 403 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carmen Calfa United States	10	294	140	131	76	70	40	406
Vivek Khemka United States	8	371 1.3×	104 0.7×	142 1.1×	71 0.9×	120 1.7×	23	519
Ghieth A. Kazkaz Saudi Arabia	6	266 0.9×	113 0.8×	103 0.8×	53 0.7×	100 1.4×	8	363
Smitha Menon United States	11	300 1.0×	128 0.9×	73 0.6×	134 1.8×	75 1.1×	18	474
Jindřich Kopecký Czechia	13	227 0.8×	168 1.2×	79 0.6×	106 1.4×	62 0.9×	57	474
Alison Lannigan United Kingdom	8	234 0.8×	61 0.4×	106 0.8×	53 0.7×	47 0.7×	21	325
Matías Chacón Argentina	13	192 0.7×	191 1.4×	67 0.5×	69 0.9×	71 1.0×	56	429
Hongfei Gao China	14	260 0.9×	174 1.2×	203 1.5×	96 1.3×	41 0.6×	52	536
Αngeliki Andrikopoulou Greece	13	220 0.7×	89 0.6×	78 0.6×	158 2.1×	30 0.4×	41	438
Yalun Li China	12	164 0.6×	163 1.2×	89 0.7×	117 1.5×	82 1.2×	39	412
Hakaru Tadokoro Brazil	10	369 1.3×	237 1.7×	76 0.6×	83 1.1×	109 1.6×	33	514

Countries citing papers authored by Carmen Calfa

Since Specialization

Citations

This map shows the geographic impact of Carmen Calfa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carmen Calfa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carmen Calfa more than expected).

Fields of papers citing papers by Carmen Calfa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carmen Calfa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carmen Calfa. The network helps show where Carmen Calfa may publish in the future.

Co-authorship network of co-authors of Carmen Calfa

This figure shows the co-authorship network connecting the top 25 collaborators of Carmen Calfa. A scholar is included among the top collaborators of Carmen Calfa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carmen Calfa. Carmen Calfa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Natori, Akina, Carmen Calfa, Alvaro J. Alencar, et al.. (2025). Characterizing unmet supportive care needs in diverse adolescent and young adult cancer survivors.. Journal of Clinical Oncology. 43(16_suppl). 11104–11104.

Silva‐Smith, Rachel, et al.. (2024). Triple Primary Cancers: An Analysis of Genetic and Environmental Factors. Cancer Prevention Research. 17(5). 209–215. 3 indexed citations

Ahn, Eugene R., Michael Rothe, Pam K. Mangat, et al.. (2024). Olaparib in Patients With Pancreatic Cancer With BRCA1/2 Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology. 1 indexed citations

Pegram, Mark D., Carmen Calfa, Christopher S. Chen, et al.. (2024). Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd).. Journal of Clinical Oncology. 42(16_suppl). TPS1121–TPS1121. 1 indexed citations

Schuetze, Scott M., Michael Rothe, Pam K. Mangat, et al.. (2024). Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology. 8(8). e2400219–e2400219. 2 indexed citations

Calfa, Carmen, et al.. (2024). The Effect of Disability and Social Determinants of Health on Breast and Cervical Cancer Screenings During the COVID-19 Pandemic. Preventing Chronic Disease. 21. E05–E05. 6 indexed citations

Mileham, Kathryn F., Michael Rothe, Pam K. Mangat, et al.. (2023). Abstract CT226: Crizotinib (C) in patients (pts) with solid tumors with MET amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Cancer Research. 83(8_Supplement). CT226–CT226. 1 indexed citations

Khalil, M.F., Michael Rothe, Pam K. Mangat, et al.. (2023). 207P Palbociclib (P) in patients (pts) with solid tumors with CDK4 or CDK6 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Annals of Oncology. 34. S265–S266. 1 indexed citations

Rothe, Michael, Pam K. Mangat, Elizabeth Garrett‐Mayer, et al.. (2023). Abstract CT231: Temsirolimus (T) in patients (pts) with solid tumors with PTEN mutation (mut): results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Cancer Research. 83(8_Supplement). CT231–CT231.

10.

Calfa, Carmen, Michael Rothe, Gordan Srkalović, et al.. (2023). Temsirolimus (T) in patients (pts) with solid tumors with PIK3CA mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology. 41(16_suppl). 3117–3117.

11.

Klute, Kelsey, Michael Rothe, Elizabeth Garrett‐Mayer, et al.. (2022). Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer WithBRAFMutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precision Oncology. 6(6). e2200191–e2200191. 16 indexed citations

12.

Penedo, Frank J., Heidy N. Medina, Patricia I. Moreno, et al.. (2022). Implementation and Feasibility of an Electronic Health Record–Integrated Patient-Reported Outcomes Symptom and Needs Monitoring Pilot in Ambulatory Oncology. JCO Oncology Practice. 18(7). e1100–e1113. 22 indexed citations

13.

Calfa, Carmen, et al.. (2022). Characterizing genitourinary exam disruptions in women presenting to a sexual health after cancer program.. Journal of Clinical Oncology. 40(16_suppl). e24048–e24048. 3 indexed citations

14.

Alva, Ajjai, Pam K. Mangat, Elizabeth Garrett‐Mayer, et al.. (2021). Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Journal of Clinical Oncology. 39(22). 2443–2451. 116 indexed citations

15.

Calfa, Carmen, Michael Rothe, Pam K. Mangat, et al.. (2021). Abstract CT173: Sunitinib (S) in patients (pts) with metastatic breast cancer (mBC) with FGFR1 mutations or amplifications: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Cancer Research. 81(13_Supplement). CT173–CT173. 1 indexed citations

16.

Fisher, Julie Gottlieb, David L. Tait, Elizabeth Garrett‐Mayer, et al.. (2020). Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Targeted Oncology. 15(6). 733–741. 30 indexed citations

17.

Norton, Nadine, Kathleen Tenner, Karla V. Ballman, et al.. (2018). Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer. Breast Cancer Research. 20(1). 52–52. 11 indexed citations

18.

Knutson, Keith L., Raphael Clynes, Barath Shreeder, et al.. (2016). Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain. Cancer Research. 76(13). 3702–3710. 47 indexed citations

19.

Clynes, Raphael, Keith L. Knutson, Karla V. Ballman, et al.. (2013). Combination trastuzumab and chemotherapy to induce immunity to multiple tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studies N0337 and N98-32-52.. Journal of Clinical Oncology. 31(15_suppl). 521–521. 3 indexed citations

20.

Calfa, Carmen, Izidore S. Lossos, Phillip Ruiz, & Janet L. Davis. (2007). Ocular Involvement as the Initial Manifestation of T-Cell Chronic Lymphocytic Leukemia. American Journal of Ophthalmology. 144(2). 326–329. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact